Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23573415 | 0.92 | RAB9A (0.45) | RAB9AGAAMEN1NPC1KMT2A | |
| SCHEMBL23573420 | 0.87 | RAB9A (0.44) | RAB9AGAAMEN1NPC1KMT2A | |
| SCHEMBL23573513 | 0.84 | GAA (0.44) | RAB9AGAALMNAPOLBPKM | |
| SCHEMBL23573401 | 0.83 | RAB9A (0.44) | RAB9AGAAMEN1NPC1KMT2A | |
| SCHEMBL23573498 | 0.82 | RAB9A (0.54) | RAB9AGAAMEN1NPC1KMT2A | |
| SCHEMBL23573282 | 0.81 | RAB9A (0.47) | RAB9AGAAMEN1NPC1KMT2A | |
| SCHEMBL23573483 | 0.81 | MEN1 (0.33) | RAB9AGAAMEN1KMT2A | |
| SCHEMBL23573372 | 0.80 | RAB9A (0.52) | RAB9AGAAMEN1NPC1KMT2A | |
| SCHEMBL23573211 | 0.79 | ALDH1A1 (0.50) | RAB9AGAANPC1PKM | |
| SCHEMBL23573225 | 0.78 | RAB9A (0.42) | RAB9AGAAMEN1NPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198239-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2021-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198239-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | ENTPD5, ADORA2A, ENTPD1 | RAB9A 2930/4885GAA 546/4885MEN1 1145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.